Risedronic Acid

Risedronic Acid

SCHEMBL3170751

O.O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FDPS

The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 12/20 0.97
BTN3A1 O00481 1/20 0.97
PDE3A Q14432 1/20 0.97
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HIF1A Q16665 1/20 0.53
GGPS1 O95749 2/20 0.49
NAPRT Q6XQN6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Risedronic Acid SCHEMBL4989214 1.00 FDPS (0.97) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL22720092 0.98 FDPS (0.94) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL18378 0.98 FDPS (1.00) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL29362587 0.98 FDPS (1.00) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL2115050 0.97 FDPS (0.97) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL3771017 0.97 FDPS (0.97) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL2115054 0.97 FDPS (0.97) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL22720090 0.95 FDPS (0.94) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL4643040 0.90 FDPS (0.83) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL5970387 0.90 FDPS (0.78) FDPSBTN3A1PDE3ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476451-B1 USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS TEVA PHARMA (IL) 2010-03-17 EP claimed
WO-2007042048-A2 METHOD FOR PREPARING CRYSTALLINE SODIUM RISEDRONATE SANDOZ A/S (DK) 2007-04-19 WO claimed
EP-1775302-A1 Method for preparing crystalline sodium risedronate Sandoz A/S (DK) 2007-04-18 EP claimed
US-7038083-B2 Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2006-05-02 US claimed
CN-1665825-A Use of certain diluents for making bisphosphonic acids TEVA PHARMA (IL) 2005-09-07 CN claimed
EP-1476451-A1 USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-11-17 EP claimed
US-20040043967-A1 Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons TEVA PHARMACEUTICALS USA, INC. 2004-03-04 US claimed
WO-2003097655-A1 USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-11-27 WO claimed
US-20100317859-A1 Process for the Preparation of Risedronate Sodium ACTAVIS GROUP PTC EHF (IS) 2010-12-16 US disclosed
US-20100121066-A1 Novel Process For Preparing Risedronic Acid ALKEM LABORATORIES LIMITED (IN) 2010-05-13 US disclosed
EP-1476451-B1 USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS TEVA PHARMA (IL) 2010-03-17 EP disclosed
US-20090209763-A1 Novel Process For Making Bisphosphonic Acids Using Diluents Other Than Halogenated Hydrocarbons LIDOR-HADAS RAMI 2009-08-20 US disclosed
WO-2009050731-A2 NOVEL PROCESS FOR PREPARING RISEDRONIC ACID ALKEM LABORATORIES LTD (IN) 2009-04-23 WO disclosed
WO-2009034580-A1 IMPROVED PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM HEMIPENTAHYDRATE FLEMING LABORATORIES LIMITED (IN) 2009-03-19 WO disclosed
US-20060128960-A1 Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons LIDOR-HADAS RAMI 2006-06-15 US disclosed
US-7038083-B2 Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2006-05-02 US disclosed
CN-1665825-A Use of certain diluents for making bisphosphonic acids TEVA PHARMA (IL) 2005-09-07 CN disclosed
EP-1476451-A1 USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-11-17 EP disclosed
US-20040043967-A1 Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons TEVA PHARMACEUTICALS USA, INC. 2004-03-04 US disclosed
WO-2003097655-A1 USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317859-A1 Process for the Preparation of Risedronate Sodium PPIP5K2, PDE8B, HMGCR FDPS 23/4885BTN3A1 4441/4885PDE3A 379/4885
US-20100121066-A1 Novel Process For Preparing Risedronic Acid PPIP5K2, PEX3, PHYKPL FDPS 666/4885BTN3A1 1162/4885PDE3A 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.